Avamys

Fluticasone furoate

Clinical data
Trade names	Flonase Sensimist, Veramyst, others
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN US DailyMed: Fluticasone furoate
Pregnancy category	AU: B3
Routes of administration	Intranasal, by mouth
ATC code	R01AD12 (WHO) R03BA09 (WHO) R03AK10 (WHO) R03AL08 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: / Rx-only EU: Rx-only
Pharmacokinetic data
Bioavailability	0.51% (Intranasal)
Protein binding	91%
Metabolism	Intranasal Liver (CYP3A4-mediated)
Elimination half-life	15 hours
Excretion	Kidney
Identifiers
IUPAC name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
CAS Number	397864-44-7
PubChem CID	9854489
DrugBank	DB08906
ChemSpider	8030195
UNII	JS86977WNV
KEGG	D06315
ChEBI	CHEBI:74899
ChEMBL	ChEMBL1676
CompTox Dashboard (EPA)	DTXSID60228586
ECHA InfoCard	100.158.130
Chemical and physical data
Formula	C27H29F3O6S
Molar mass	538.58 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
InChI InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1 Key:XTULMSXFIHGYFS-VLSRWLAYSA-N

Fluticasone furoate, sold under the brand name Flonase Sensimist and formerlyVeramyst, among others, is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray. It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol. Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.

It was approved for medical use in the United States in April 2007, and in the European Union in November 2008. In 2020, fluticasone was the 23rd most commonly prescribed medication in the United States, with more than 24 million prescriptions.

Society and culture

Brand names

In the US it is marketed by GlaxoSmithKline for asthma as Arnuity Ellipta and is only available with a prescription. It is marketed over-the-counter for allergic rhinitis as Flonase Sensimist. The Veramyst brand name has been discontinued in the US. It is also marketed as Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, Italy, India, Taiwan and South Korea).

The combination drugs fluticasone furoate/umeclidinium bromide/vilanterol, marketed as Trelegy Ellipta, and fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada, New Zealand) and Relvar Ellipta (EU, UK), are approved for use in the United States for long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). They are also approved for the treatment of asthma.

See also

• Fluticasone furoate/umeclidinium bromide/vilanterol
• Fluticasone propionate/salmeterol

External links

• "Fluticasone furoate". Drug Information Portal. U.S. National Library of Medicine.